Associated tags: Tokyo Stock Exchange, Therapy, Science, PDC, Quality of life, Patient, Biotechnology, Pharmaceutical, Health, Research, Fine chemical, Pharmaceutical industry, Radiology
Locations: EUROPE, SWITZERLAND, JAPAN, ASIA PACIFIC, TOKYO
Research,
Hospitals,
Clinical Trials,
Biotechnology,
Radiology,
Health,
Pharmaceutical,
Science,
Oncology,
CAIX,
Patient,
Safety,
PET/CT,
Pharmacokinetics,
National Cancer Center,
Renal cell carcinoma,
Carbonic anhydrase,
Neoplasm,
PET,
Pharmaceutical industry National Cancer Center and PeptiDream Inc.:
Key Points:
- National Cancer Center and PeptiDream Inc.:
The National Cancer Center (President: Hitoshi Nakagama) Hospital East (Director: Toshihiko Doi) and PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) today announced the dosing of the first patient in the human imaging study of PeptiDream’s 64Cu-PD-32766, a 64Cu-labelled radiopharmaceutical targeting Carbonic Anhydrase IX (CAIX), for patients with clear cell renal cell carcinoma (ccRCC) conducted at the National Cancer Center Hospital East (“the clinical research”).
- The clinical research, which was approved by the National Cancer Center Japan’s clinical review board in April 2024, is a first-in-human imaging study of 64Cu-PD-32766 conducted in collaboration with the National Cancer Center Japan and PeptiDream.
- This study is intended to evaluate the safety, pharmacokinetics, and accumulation of 64Cu-PD-32766 in tumors using PET in patients with newly diagnosed, relapsed or suspected relapsed ccRCC.
- To evaluate the safety, pharmacokinetics, and exposure dose of PET/CT test with 64Cu-PD-32766 in patients with newly diagnosed, relapsed or suspected to have relapsed ccRCC.
Health,
Research,
Radiology,
Pharmaceutical,
Science,
Biotechnology,
RLT,
Oncology,
NVS,
JPY,
Partnership,
PDC,
Patient,
Peptide,
Pharmaceutical industry PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG (“hereinafter Novartis”) (NYSE: NVS).
Key Points:
- PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG (“hereinafter Novartis”) (NYSE: NVS).
- Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (“PDPS®”) technology to identify and optimize novel macrocyclic peptides against targets selected by Novartis, for potential conjugation to radionuclides (to which Novartis refers to as “radioligand therapies” or “RLTs”) or other applications for both therapeutic and diagnostic purposes.
- Under the terms of the agreement, PeptiDream will receive an upfront payment of $180 million USD (28.03 billion JPY*1) from Novartis.
- “We are delighted to further expand our long-standing macrocyclic peptide discovery collaboration with Novartis, adding additional peptide RLT and other programs to our strong partnership,” said Patrick C. Reid, Ph.D., CEO of PeptiDream.
Retrieved on:
Wednesday, September 20, 2023
Biotechnology,
Health,
Radiology,
Pharmaceutical,
Clinical Trials,
Roche,
Patient,
USD,
Fine chemical,
Pharmaceutical industry,
Genentech Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (“PDPS”) technology to discover, optimize, and develop macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to Genentech.
Key Points:
- Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (“PDPS”) technology to discover, optimize, and develop macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to Genentech.
- PeptiDream will lead early preclinical development before transitioning peptide-RI drug conjugate products arising from the collaboration to Genentech for further development and commercialization.
- “We are extremely excited to announce this new collaboration with Genentech for the discovery and development of peptide-RI drug conjugates.
- PeptiDream is a global leader in the discovery and development of peptide-RI conjugates, and through our PDRadiopharma, is one of the leading radiopharmaceutical companies in Japan.
Biotechnology,
Health,
Science,
Pharmaceutical,
Research,
Drug discovery,
Therapy,
Astellas Pharma,
Patient,
Peptide,
Fine chemical Astellas Pharma Inc. (TOKYO: 4503, President and CEO: Naoki Okamura, “Astellas”) and PeptiDream Inc. (TOKYO: 4587, President and CEO: Patrick C. Reid, “PeptiDream”) today announced a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas.
Key Points:
- Astellas Pharma Inc. (TOKYO: 4503, President and CEO: Naoki Okamura, “Astellas”) and PeptiDream Inc. (TOKYO: 4587, President and CEO: Patrick C. Reid, “PeptiDream”) today announced a research collaboration and license agreement to discover novel protein degraders for two targets selected by Astellas.
- Under the agreement between the two companies, Astellas will have the option to select up to three additional targets to be included in the collaboration.
- Astellas focuses on targeted protein degraders directed to undruggable targets that are difficult to approach with conventional technologies.
- PeptiDream is also eligible to receive single-digit percent royalty payments on net sales of any products arising from the collaboration.
Retrieved on:
Wednesday, March 22, 2023
Oncology,
Health,
Radiology,
Research,
Science,
Pharmaceutical,
Biotechnology,
GPC3,
EASL,
Partnership,
Radionuclide,
Liver cancer,
Death,
Neoplasm,
Fine chemical PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced the nomination of the second targeted peptide radiopharmaceutical clinical development candidate arising from their strategic partnership with RayzeBio, Inc., (“RayzeBio”), a privately held California-based targeted radiopharmaceutical company developing innovative cancer drugs.
Key Points:
- PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced the nomination of the second targeted peptide radiopharmaceutical clinical development candidate arising from their strategic partnership with RayzeBio, Inc., (“RayzeBio”), a privately held California-based targeted radiopharmaceutical company developing innovative cancer drugs.
- The development candidate is a novel first-in-class macrocyclic peptide-radioisotope (RI) conjugate against Glypican-3 (“GPC3”) expressed in liver cancers.
- The peptide-RI development candidate was discovered using PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) and demonstrated potent and selective GPC3 binding, rapid cellular internalization, and sustained tumor specific uptake and anti-tumor efficacy in pre-clinical models at RayzeBio.
- PeptiDream and RayzeBio have an ongoing multi-program collaboration, initiated in August 2020, to screen and identify novel peptide binders against tumor antigens for the targeted delivery of radioisotopes.
Retrieved on:
Tuesday, December 27, 2022
Biotechnology,
Health,
Science,
Pharmaceutical,
Research,
Disease,
Tissue,
PDC,
Cell,
Therapy,
Global Research Collaboration for Infectious Disease Preparedness,
PDPS,
Pharmaceutical industry,
Lilly Under the agreement, PeptiDream will utilize its proprietary Peptide Discovery Platform System (“PDPS”) technology to identify high affinity macrocyclic peptide ligands to Lilly-elected targets of interest, capable of delivering a Lilly conjugated payload to certain cells and tissues of interest to Lilly.
Key Points:
- Under the agreement, PeptiDream will utilize its proprietary Peptide Discovery Platform System (“PDPS”) technology to identify high affinity macrocyclic peptide ligands to Lilly-elected targets of interest, capable of delivering a Lilly conjugated payload to certain cells and tissues of interest to Lilly.
- PeptiDream will lead peptide discovery and optimization efforts, and Lilly will lead payload discovery and optimization efforts.
- Lilly will be responsible for all development aspects of any PDC products arising from the collaboration.
- “I am delighted to announce this collaboration with Lilly and greatly look forward to utilizing our peptide discovery and optimization capabilities to generate peptide ligands capable of delivering Lilly payloads to specific cells and tissues to develop novel and innovative PDC therapeutics to treat disease.
Retrieved on:
Tuesday, December 27, 2022
Health,
Other Health,
Research,
Pharmaceutical,
Science,
Biotechnology,
MSD,
Christian democracy,
PDC,
Therapy,
Pharmaceutical industry Under the agreement, PeptiDream will provide peptide candidates identified from PeptiDream’s proprietary Peptide Discovery Platform System (“PDPS”) technology for use as PDCs against targets of interest to MSD.
Key Points:
- Under the agreement, PeptiDream will provide peptide candidates identified from PeptiDream’s proprietary Peptide Discovery Platform System (“PDPS”) technology for use as PDCs against targets of interest to MSD.
- MSD will have exclusive rights to the peptide candidates for conjugation to cytotoxic payloads and will be responsible for all development aspects of any PDC products arising from the collaboration.
- The new collaboration and license agreement builds upon the long collaborative relationship between the companies, which started with a multi-target discovery and optimization collaboration in April 2015.
- “I am excited to announce this collaboration with MSD for the discovery and development of peptide drug conjugates, to further expand on our pipeline of innovative PDC therapeutics.
Retrieved on:
Wednesday, November 6, 2019
They are comprised of a proprietary antibody-binding domain linked to a highly specific tumor-binding domain.
Key Points:
- They are comprised of a proprietary antibody-binding domain linked to a highly specific tumor-binding domain.
- They work by creating a bridge between antibodies and cancer cells that leads to immune-mediated killing of the tumor.
- "Kleo is honored to present preclinical proof-of-concept data for our CD38-ARMs at ASH, which supports the advancement of this exciting and novel technology platform into the clinic," said Doug Manion, Kleo's Chief Executive Officer.
- Overall, the data demonstrated the value of ARM compounds as a platform to develop compounds tailored to a specific indication.
